A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients

Fisher, 1993, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma, N Engl J Med, 328, 1002, 10.1056/NEJM199304083281404 Dixon, 1986, Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience, J Clin Oncol, 4, 295, 10.1200/JCO.1986.4.3.295 Coiffier, 2002, CHOP plus rituximab with CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma. A Groupe d'Etude des Lymphomes de l'Adulte study, N Engl J Med, 346, 235, 10.1056/NEJMoa011795 Sehn, 2005, Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia, J Clin Oncol, 23, 5027, 10.1200/JCO.2005.09.137 Feugier, 2005, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte, J Clin Oncol, 23, 4117, 10.1200/JCO.2005.09.131 Pfreundschuh, 2006, Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the completed RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL), Blood, 108, 64a, 10.1182/blood.V108.11.205.205 Anderson, 1984, Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation, Blood, 63, 1424, 10.1182/blood.V63.6.1424.1424 Press, 1999, Radiolabeled antibody therapy of B-cell lymphomas, Semin Oncol, 26, 58 Witzig, 1999, Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma, J Clin Oncol, 17, 3793, 10.1200/JCO.1999.17.12.3793 Gordon, 2004, Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study, Blood, 103, 4429, 10.1182/blood-2003-11-3883 Morschhauser, 2007, Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation, Blood, 110, 54, 10.1182/blood-2007-01-068056 Harris, 1999, World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, 1997, J Clin Oncol, 17, 3835, 10.1200/JCO.1999.17.12.3835 Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 Fleming, 1982, One-sample multiple testing procedure for phase II clinical trials, Biometrics, 38, 143, 10.2307/2530297 Machin, 1987 A'Hern, 2001, Sample size tables for exact single-stage phase II designs, Stat Med, 20, 859, 10.1002/sim.721 Kaplan, 1958, Non-parametric estimationn from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 1993, The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma, N Engl J Med, 329, 987, 10.1056/NEJM199309303291402 Kaminski, 2005, 131I-tositumomab therapy as initial treatment for follicular lymphoma, N Engl J Med, 352, 441, 10.1056/NEJMoa041511 Press, 2003, A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911, Blood, 102, 1606, 10.1182/blood-2003-01-0287 Press, 2006, Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911, J Clin Oncol, 24, 4143, 10.1200/JCO.2006.05.8198 Hamlin, 2005, Early safety and efficacy analysis of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (Zevalin) for elderly high risk patients with untreated DLBCL, Blood, 106, 10.1182/blood.V106.11.926.926